The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Complementary business models are the reason for the acquisition
The govt has rolled out three schemes for promoting the manufacture of API
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
Subscribe To Our Newsletter & Stay Updated
